Xilio Therapeutics, Inc.XLONASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+69.7%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+69.7%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
4.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 86.57% |
| Q2 2025 | -3.72% |
| Q1 2025 | -1.63% |
| Q4 2024 | 7.68% |
| Q3 2024 | -0.39% |
| Q2 2024 | 15.91% |
| Q1 2024 | 3.55% |
| Q4 2023 | -4.43% |
| Q3 2023 | 13.70% |
| Q2 2023 | 14.49% |
| Q1 2023 | -1.55% |
| Q4 2022 | -14.65% |
| Q3 2022 | 17.70% |
| Q2 2022 | -15.68% |
| Q1 2022 | -8.53% |
| Q4 2021 | -22.52% |
| Q3 2021 | 30.63% |
| Q2 2021 | -39.27% |
| Q1 2021 | 19.79% |
| Q4 2020 | -40.84% |
| Q3 2020 | -27.75% |
| Q2 2020 | -44.94% |
| Q1 2020 | 0.00% |